<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03623672</url>
  </required_header>
  <id_info>
    <org_study_id>201712025</org_study_id>
    <secondary_id>R34AG056639</secondary_id>
    <nct_id>NCT03623672</nct_id>
  </id_info>
  <brief_title>North American Prodromal Synucleinopathy Consortium</brief_title>
  <acronym>NAPS</acronym>
  <official_title>North American Prodromal Synucleinopathy Consortium</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Minnesota</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of California, Los Angeles</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>McGill University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Emory University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute on Aging (NIA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Banner Health</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Portland VA Medical Center</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>Washington University School of Medicine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will enroll participants with idiopathic rapid eye movement (REM) sleep behavior
      disorder (RBD), for the purpose of preparing for a clinical trial of neuroprotective
      treatments against synucleinopathies.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      REM sleep behavior disorder (RBD) is a rare disorder where people act out their dreams.
      People with RBD often, but not always, develop Parkinson's Disease, dementia with Lewy
      bodies, multiple system atrophy, or other neurodegenerative diseases of the synucleinopathy
      type. The North American Prodromal Synucleinopathy (NAPS) Consortium was formed with the
      purpose of enrolling participants with RBD, in anticipation of a future clinical trial of a
      neuroprotective treatment against synucleinopathies. The NAPS Consortium will collect
      standardized clinical assessments, biofluids, and other data in order to develop biomarkers
      for synucleinopathies in the prodromal (presymptomatic) stage as well as a trial-ready
      registry of participants. Participants procedures will include a ~2-hour clinical assessment
      (medical history and physical exam), questionnaires, blood draw, and (at select sites)
      optional lumbar puncture.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 29, 2018</start_date>
  <completion_date type="Anticipated">July 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2021</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>2 Years</target_duration>
  <primary_outcome>
    <measure>Prodromal Synucleinopathy Rating Scale</measure>
    <time_frame>2 years</time_frame>
    <description>Rating scale combining neurocognitive battery, motor, autonomic, olfaction, color vision functions. Global score range 0-3, with higher score indicating greater symptoms of synucleinopathy.</description>
  </primary_outcome>
  <enrollment type="Anticipated">360</enrollment>
  <condition>REM Sleep Behavior Disorder</condition>
  <condition>Parkinson Disease</condition>
  <condition>Lewy Body Disease</condition>
  <condition>Dementia With Lewy Bodies</condition>
  <condition>Multiple System Atrophy</condition>
  <condition>REM Sleep Parasomnias</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood (plasma, buffy coat, extracted DNA) and cerebrospinal fluid
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Idiopathic REM sleep behavior disorder, adults.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Idiopathic REM sleep behavior disorder

        Exclusion Criteria:

          -  REM sleep behavior disorder secondary to another cause (ex: narcolepsy, dementia,
             Parkinson's Disease, etc)

          -  Other neurological disorder
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yo-El Ju, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Washington University School of Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Bradley Boeve, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yo-El Ju, MD</last_name>
    <phone>314-747-6124</phone>
    <email>info@naps-rbd.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jennifer McLeland</last_name>
    <email>naps@wustl.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Banner Sun Health Research Institute</name>
      <address>
        <city>Sun City</city>
        <state>Arizona</state>
        <zip>85351</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daneva MinerRose</last_name>
      <phone>623-832-5468</phone>
      <email>Daneva.MinerRose@bannerhealth.com</email>
    </contact>
    <contact_backup>
      <last_name>Marissa Keane</last_name>
      <phone>623-832-6512</phone>
      <email>marissa.keane@bannerhealth.com</email>
    </contact_backup>
    <investigator>
      <last_name>David Shprecher, DO</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adreanne Rivera</last_name>
      <phone>310-794-0213</phone>
      <email>adreannerivera@mednet.ucla.edu</email>
    </contact>
    <investigator>
      <last_name>Alon Avidan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Redwood City</city>
        <state>California</state>
        <zip>94063</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adrian Ekelmans</last_name>
      <phone>650-721-5489</phone>
      <email>adrian01@stanford.edu</email>
    </contact>
    <investigator>
      <last_name>Emmanuel During, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kelsey Tucker</last_name>
      <phone>404-712-3529</phone>
      <email>kelsey.ann.tucker@emory.edu</email>
    </contact>
    <investigator>
      <last_name>Daniel Huddleston, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Donald Bliwise, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02145</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthew Stauder</last_name>
      <phone>617-726-9589</phone>
      <email>mstauder@mgh.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>Aleksandar Videnovic, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Josh De Kam</last_name>
      <phone>612-626-8052</phone>
      <email>jadekam@umn.edu</email>
    </contact>
    <investigator>
      <last_name>Michael Howell, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ruth Kraft</last_name>
      <phone>507-284-1324</phone>
      <email>kraft.ruth@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Bradley Boeve, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Erik St Louis, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington University</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer McLeland</last_name>
      <phone>314-747-6124</phone>
      <email>naps@wustl.edu</email>
    </contact>
    <investigator>
      <last_name>Yo-El Ju, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Portland VA Medical Center</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alisha McBride</last_name>
      <phone>503-220-8262</phone>
      <phone_ext>5320</phone_ext>
      <email>mcbridal@ohsu.edu</email>
    </contact>
    <investigator>
      <last_name>Miranda Lim, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>McGill University</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <zip>HGH 2R9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amelie Pelletier</last_name>
      <phone>514-934-1934</phone>
      <phone_ext>45462</phone_ext>
      <email>amelie.pelletier@mail.mcgill.ca</email>
    </contact>
    <investigator>
      <last_name>Ronald Postuma, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>August 6, 2018</study_first_submitted>
  <study_first_submitted_qc>August 6, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 9, 2018</study_first_posted>
  <last_update_submitted>July 14, 2020</last_update_submitted>
  <last_update_submitted_qc>July 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>sleep</keyword>
  <keyword>REM</keyword>
  <keyword>rapid eye movement</keyword>
  <keyword>parkinson</keyword>
  <keyword>lewy body disease</keyword>
  <keyword>dementia with lewy bodies</keyword>
  <keyword>Multiple System Atrophy</keyword>
  <keyword>parasomnia</keyword>
  <keyword>synuclein</keyword>
  <keyword>synucleinopathy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
    <mesh_term>Dementia</mesh_term>
    <mesh_term>Multiple System Atrophy</mesh_term>
    <mesh_term>Shy-Drager Syndrome</mesh_term>
    <mesh_term>Lewy Body Disease</mesh_term>
    <mesh_term>REM Sleep Behavior Disorder</mesh_term>
    <mesh_term>Parasomnias</mesh_term>
    <mesh_term>REM Sleep Parasomnias</mesh_term>
    <mesh_term>Atrophy</mesh_term>
    <mesh_term>Mental Disorders</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>This project will develop a large database of potential neurocognitive and polysomnographic biomarkers in rapid eye movement sleep behavior disorder (RBD), as well as a biobank of blood, DNA, and cerebrospinal fluid from individuals with RBD. Since individuals with RBD frequently develop synucleinopathies including Parkinson Disease, Dementia with Lewy Bodies (DLB), and Multiple System Atrophy, we anticipate that the data and samples we collect will be valuable for investigators interested in synucleinopathies, other dementias such as Alzheimer's Disease (AD), and sleep disorders. The neurocognitive battery will contain all components of the Uniform Dataset version 3 (UDS 3) with the additional DLB module, to harmonize with research efforts in AD and DLB. Biofluid samples will be banked at the National Cell Repository for Alzheimer's Disease (NCRAD) to facilitate distribution to other investigators.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_time_frame>Data will be made available after primary analyses planned by NAPS investigators in 2020. Data will be available indefinitely.</ipd_time_frame>
    <ipd_access_criteria>IPD and sample requests will be determined by a Steering Committee</ipd_access_criteria>
    <ipd_url>http://naps-rbd.org</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

